News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Author: mark

Epigenomics AG: CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous31.08.2020 / 07:34 The issuer is solely responsible for the content of this announcement. CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible Berlin (Germany) and San Diego, CA (USA), August 31, 2020 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; […]

Read more

Epigenomics AG presents operational highlights and reports financial results for first six months of 2020

DGAP-News: Epigenomics AG / Key word(s): Half Year Results/Quarter Results13.08.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG presents operational highlights and reports financial results for first six months of 2020 Berlin (Germany) and San Diego, CA (U.S.A.), August 13, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, […]

Read more

New study published in the Journal of the National Cancer Institute concludes that Epi proColon(R) is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening

DGAP-News: Epigenomics AG / Key word(s): Study results/Study10.08.2020 / 08:00 The issuer is solely responsible for the content of this announcement. New study published in the Journal of the National Cancer Institute concludes that Epi proColon(R) is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening […]

Read more

Epigenomics AG to Participate in Raymond James Human Health Innovations Conference

DGAP-News: Epigenomics AG / Key word(s): Conference/Miscellaneous16.06.2020 / 10:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG to Participate in Raymond James Human Health Innovations Conference Berlin (Germany) and San Diego, CA (U.S.A.), June 16, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced that company management […]

Read more

Epigenomics AG Reports 2020 First Quarter Financial Results

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results07.05.2020 / 08:17 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports 2020 First Quarter Financial Results Berlin (Germany) and San Diego, CA (U.S.A.), May 7, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today announced financial results […]

Read more

Epigenomics AG Reports Financial Results for Fiscal Year 2019 and Preliminary Unaudited Financial Results for the First Quarter of 2020

DGAP-News: Epigenomics AG / Key word(s): Annual Results29.04.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for Fiscal Year 2019 and Preliminary Unaudited Financial Results for the First Quarter of 2020 Berlin (Germany) and San Diego, CA (USA), April 29, 2020 – Epigenomics AG (FSE: […]

Read more